Clinical Trial SuccessThe pivotal ARES P3 study exceeded expectations with a 62% GI-ORR at day 28, well above the anticipated 38%.
Market Adoption PotentialAs there is currently no FDA-approved therapy for third-line GI-aGvHD, MaaT013 can achieve broad adoption in the third-line treatment setting due to its favorable efficacy and safety advantage.
Regulatory ProgressMaaT013 is about to secure its first regulatory approval, and MaaT033 has demonstrated its excellent safety in both post allo-HSCT and ALS.